Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ERNA

Ernexa Therapeutics Inc

Apr 30 • 10:22AM ET

0.1532

-0.0342 -18.28 %

Healthcare • Biotechnology • USA • Nano • NASD

Today, 9:05 AMErnexa Therapeutics to implement 1-for-25 reverse stock split effective May 4, 2026 to regain Nasdaq $1.00 bid-price compliance

Peers: CRSP NTLA EDIT CLLS QURE REPL BLUE SGMO VYGR PSTX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.26	Insider Own	31.68%	Shs Outstand	29.15M	Perf Week	-19.82%
Market Cap	4.46M	Forward P/E	-	EPS next Y	-	Insider Trans	76.46%	Shs Float	19.92M	Perf Month	-23.04%
Enterprise Value	3.07M	PEG	-	EPS next Q	-	Inst Own	1.79%	Short Float	1.01%	Perf Quarter	-87.24%
Income	-14.10M	P/S	-	EPS this Y	-	Inst Trans	0.11%	Short Ratio	0.11	Perf Half Y	-87.75%
Sales	0.00M	P/B	0.50	EPS next Y	-	ROA	-253.68%	Short Interest	0.20M	Perf YTD	-87.24%
Book/sh	0.31	P/C	2.37	EPS next 5Y	-	ROE	-686.64%	52W High	4.02 -96.19%	Perf Year	-95.07%
Cash/sh	0.06	P/FCF	-	EPS past 3/5Y	73.56% 69.90%	ROIC	-526.47%	52W Low	0.18 -16.77%	Perf 3Y	-99.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.19% 7.29%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	97.02%	Oper. Margin	-	ATR (14)	0.02	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	1.01	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	27.79	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.01	EPS Q/Q	88.58%	SMA20	-22.08%	Beta	2.08	Target Price	9.00
Payout	-	Debt/Eq	0.20	Sales Q/Q	-100.00%	SMA50	-36.85%	Rel Volume	1.95	Prev Close	0.19
Employees	5	LT Debt/Eq	0.12	Earnings	-	SMA200	-85.58%	Avg Volume	1.77M	Price	0.15
IPO	Aug 29, 1991	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	611,460	Change	-18.28%

Today 09:00AM	Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split (GlobeNewswire) -18.28%
Mar-31-26 08:55AM	Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 (GlobeNewswire) +5.29%
Feb-20-26 09:05AM	Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series (GlobeNewswire) -17.25%
Feb-06-26 09:25AM	Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering (GlobeNewswire) -44.66%
Feb-03-26 08:45AM	Ernexa Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA (GlobeNewswire) -25.80%
08:45AM	Loading…
Jan-27-26 08:45AM	Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program (GlobeNewswire)
Jan-06-26 08:15AM	Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer (GlobeNewswire)
Dec-08-25 08:30AM	Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer (GlobeNewswire)
Dec-03-25 08:30AM	Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-02-25 08:50AM	Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG (GlobeNewswire)
Nov-11-25 07:00AM	Ernexa Therapeutics to Present at Oxford Global's Cell 2025 (GlobeNewswire) -5.39%
Nov-10-25 08:35AM	Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials (GlobeNewswire)
Nov-06-25 09:15AM	Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform (GlobeNewswire)
Oct-29-25 08:33AM	Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer (PR Newswire) +40.80%
Oct-01-25 08:30AM	Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa (GlobeNewswire)
08:30AM	Loading…
Sep-29-25 08:30AM	Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit (GlobeNewswire)
Sep-17-25 08:30AM	Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research (GlobeNewswire) -5.22%
Sep-10-25 08:30AM	Ernexa Therapeutics Provides Update on Operational Excellence and Performance (GlobeNewswire)
Sep-03-25 09:30AM	Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Jul-09-25 08:30AM	Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Jun-25-25 08:30AM	Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development (GlobeNewswire) -5.05%
Jun-24-25 08:30AM	Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement (GlobeNewswire) -17.50%
Jun-11-25 09:35AM	Ernexa Therapeutics announces 1-for-15 reverse stock split (TipRanks)
Jun-10-25 09:30AM	Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split (GlobeNewswire) -17.99%
May-28-25 08:30AM	Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 (GlobeNewswire)
May-14-25 08:30AM	Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations (GlobeNewswire) +13.11%
May-08-25 08:30AM	Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-29-25 08:30AM	Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-22-25 08:30AM	Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-03-25 08:55AM	Ernexa Therapeutics Closes New Funding Round (GlobeNewswire) -5.24%
08:30AM	Loading…
Mar-25-25 08:30AM	Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease (GlobeNewswire) -5.77%
Feb-26-25 08:30AM	Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline (GlobeNewswire)
Jan-29-25 08:46AM	Eterna appoints Zeldis, Sather to scientific advisory board (TipRanks)
Jan-28-25 08:30AM	Eterna Therapeutics Announces Expansion of Scientific Advisory Board (GlobeNewswire)
Jan-14-25 08:30AM	Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer (GlobeNewswire) +48.22%
Jan-09-25 07:30AM	Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors (GlobeNewswire)
Dec-03-24 08:30AM	Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models (GlobeNewswire) -9.95%
Nov-25-24 08:30AM	Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program (GlobeNewswire)
Nov-14-24 08:30AM	Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing (GlobeNewswire)
Oct-30-24 08:30AM	Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success (GlobeNewswire)
Oct-18-24 08:06AM	Eterna, Factor announce license, collaboration agreement (TipRanks)
Oct-17-24 08:00AM	Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases (GlobeNewswire)
May-14-24 10:53PM	ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024 (InvestorPlace) +9.81% -9.79%
May-10-24 08:00AM	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases (GlobeNewswire) -6.48%
May-08-24 09:31AM	Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board (GlobeNewswire) +12.12%
May-07-24 08:00AM	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus (GlobeNewswire) +12.50%
08:00AM	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases (GlobeNewswire)
Mar-15-24 08:53AM	ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Feb-20-24 08:30AM	Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors (GlobeNewswire)
Jan-03-24 04:15PM	Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) (GlobeNewswire)
Dec-21-23 11:18AM	Eterna Therapeutics Appoints Sanjeev Luther as President and CEO (Exec Edge)
Dec-20-23 04:15PM	Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer (GlobeNewswire) +9.88%
Dec-14-23 06:56PM	Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing (GlobeNewswire) +29.29% -16.57%
Nov-02-23 11:48AM	Eterna Therapeutics Appoints Dr. James Bristol to Board of Directors (Exec Edge) +8.13%
Nov-01-23 08:30AM	Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors (GlobeNewswire) -12.76%
Sep-06-23 01:01PM	Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies (Exec Edge)
09:40AM	EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics (Benzinga)
08:00AM	Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics (GlobeNewswire)
Sep-05-23 11:24AM	Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors (Exec Edge)
08:30AM	Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors (GlobeNewswire)
Jul-18-23 02:24PM	Eterna Therapeutics Announces $8.7M Private Placement Transaction (Exec Edge) +8.89%
08:00AM	Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing (GlobeNewswire)
Jul-11-23 11:21AM	Eterna Therapeutics Appoints Industry Veterans Binder, Wagner to Board of Directors (Exec Edge) +6.52%
08:30AM	Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors (GlobeNewswire)
May-24-23 11:18AM	Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel (Exec Edge) -5.41%
08:30AM	Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel (GlobeNewswire)
May-17-23 08:30AM	Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire) -5.73%
May-04-23 08:30AM	Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire)
May-03-23 01:40PM	Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis (Exec Edge)
May-02-23 07:30AM	Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics (GlobeNewswire)
Apr-11-23 08:00AM	Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million (GlobeNewswire)
Mar-28-23 08:30AM	Jeff Karp, Ph.D., Joins Eternas Scientific Advisory Board (GlobeNewswire)
Mar-20-23 04:10PM	Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights (GlobeNewswire) -7.74%
Mar-16-23 07:04AM	Insiders might want to re-evaluate their US$2.7m stock purchase as Eterna Therapeutics Inc. (NASDAQ:ERNA) drops to US$16m (Simply Wall St.) +10.00%
Feb-22-23 09:46AM	EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology (Benzinga)
08:00AM	Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications (GlobeNewswire)
Jan-04-23 08:30AM	Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President (GlobeNewswire) +8.06%
Dec-20-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics (ACCESSWIRE)
Nov-01-22 08:30AM	Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies (GlobeNewswire)
Oct-18-22 08:30AM	Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress (GlobeNewswire) +10.98%
Oct-17-22 08:30AM	Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics (GlobeNewswire) +19.94%

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cherington Charles	10% Owner	Feb 10 '26	Buy	0.50	4,000,000	2,000,000	6,779,440	Feb 17 09:14 PM
Cherington Charles	10% Owner	Jun 09 '25	Buy	0.10	21,241,163	2,221,826	41,659,743	Jun 11 08:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ERNA

Ernexa Therapeutics Inc

Upgrade your Finviz experience